University of New Mexico, Albuquerque, NM
Rodrigo Rodriguez , Melissa Gonzalez , Bridget N. Fahy , Anita Kinney , Ashwani Rajput
Background: Although incidence rates for colorectal cancer (CRC) for Hispanics are similar to non-Hispanic whites (NHW) in New Mexico, the cause-specific mortality is higher among the Hispanic population. Hispanics have also been shown to be less likely to be current with colorectal cancer screening guidelines as compared to NHW. The purpose of this study was to determine if there was a difference between Hispanics and NHW in stage at presentation and if the care provided was concordant with NCCN guidelines at our NCI designated cancer center. Methods: A prospective data base of all patients who presented with colorectal cancer between June 2009 and July 2013 was queried. A total of 197 patients were identified. Data was extracted that included: demographics, stage of CRC at first diagnosis, treatments given, and pathology results. Frequencies of stage at presentation and NCCN guideline concordance (meeting the 12 lymph node metric, receipt of adjuvant therapy for stage III disease and radiation therapy for locally advanced rectal cancer) were recorded. Results: The Table shows the results. There were 107 (55%) males. There was not a statistical difference in the stage of presentation for Hispanics and NHW for patients with colon cancer. Hispanic patients with rectal cancer, however, presented with more advanced stage of disease as compared to NHW (p<0.05). There was no statistically significant difference in concordance with NCCN guidelines for the three metrics analyzed. Conclusions: Hispanics and NHW with colon cancer presented with similar stage of disease and were concordant with NCCN guideline metrics. Hispanics with rectal cancer, however, presented at a more advanced stage of disease as compare to NHW patients. The reason for this disparity remains to be elucidated. Future studies to include outreach, education, screening and molecular profiling of these disparate populations are planned.
Colon (stage) | Rectal (stage) | 12 LN | Adj chemo stage III |
XRT rectal cancer |
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
I | II | III | IV | I | II | III | IV | Colon | Rectal | |||
Hispanic | 21.8% | 27.3% | 23.6% | 27.3% | 6.4% | 19.4% | 61.3% | 12.9% | 91% | 85% | 85% | 86% |
NHW | 17.4% | 26.1% | 26.1% | 30.4% | 34.5% | 13.8% | 41.4% | 10.3% | 91% | 91% | 85% | 72% |
Other | 18.8% | 25% | 31.2% | 25% | 25% | 25% | 43.8% | 6.2% | 93% | 67% | 89% | 69% |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Quality Care Symposium
First Author: Kimberley Lynn Newcomer
2023 ASCO Annual Meeting
First Author: Kim Newcomer
2023 ASCO Annual Meeting
First Author: Fang Gu
2022 ASCO Annual Meeting
First Author: Hui Xie